Treffer 1 - 7 von 7 für Suche 'Babicz, Tamás', Suchdauer: 0,64s Treffer weiter einschränken
  1. 1
    Double Heterozygosity for Rare Deleterious Variants in the BRCA1 and BRCA2 Genes in a Hungarian Patient with Breast Cancer

    Double Heterozygosity for Rare Deleterious Variants in the BRCA1 and BRCA2 Genes in a Hungarian Patient with Breast Cancer von Madar, László, Majoros, Viktória, Szűcs, Zsuzsanna, Nagy, Orsolya, Babicz, Tamás, Butz, Henriett, Patócs, Attila, Balogh, István, Koczok, Katalin


    Volltext
    Artikel

    Zu den Favoriten
    Gespeichert in:
  2. 2
    Double Heterozygosity for Rare Deleterious Variants in the IBRCA1/I and IBRCA2/I Genes in a Hungarian Patient with Breast Cancer

    Double Heterozygosity for Rare Deleterious Variants in the IBRCA1/I and IBRCA2/I Genes in a Hungarian Patient with Breast Cancer von Madar, László, Majoros, Viktória, Szűcs, Zsuzsanna, Nagy, Orsolya, Babicz, Tamás, Butz, Henriett, Patócs, Attila, Balogh, István, Koczok, Katalin


    Volltext
    Artikel

    Zu den Favoriten
    Gespeichert in:
  3. 3
    PD32-03 A PHASE 2 OPEN-LABEL TRIAL OF GTX-758 IN MEN WITH CASTRATION-RESISTANT PROSTATE CANCER, FINAL ANALYSIS OF THE PRIMARY ENDPOINT

    PD32-03 A PHASE 2 OPEN-LABEL TRIAL OF GTX-758 IN MEN WITH CASTRATION-RESISTANT PROSTATE CANCER, FINAL ANALYSIS OF THE PRIMARY ENDPOINT von Aronson, William, Yu, Evan, Hancock, Michael, Babicz, Tamás, Tutrone, Ronald, Ng, Christopher, Belkoff, Laurence, Pápai, Zsuzsanna, Géczi, Lajos, Getzenberg, Robert

    Veröffentlicht in The Journal of urology

    Volltext
    Artikel

    Zu den Favoriten
    Gespeichert in:
  4. 4
    Effect of the ERα agonist, GTx-758 (250 mg daily), on total and free testosterone, and PSA, in men with castration resistant prostate cancer (CRPC) maintained on LHRH therapy

    Effect of the ERα agonist, GTx-758 (250 mg daily), on total and free testosterone, and PSA, in men with castration resistant prostate cancer (CRPC) maintained on LHRH therapy von Yu, Evan Y., Hancock, Michael L., Babicz, Tamas, Aronson, William J., Papai, Zsuzsanna, Geczi, Lajos, Getzenberg, Robert H.

    Veröffentlicht in Journal of clinical oncology

    Volltext
    Artikel

    Zu den Favoriten
    Gespeichert in:
  5. 5
    Evaluation of the ERα agonist, GTx-758 (250 mg daily), in men with metastatic (mCRPC) and nonmetastatic castration-resistant prostate cancer (nmCRPC)

    Evaluation of the ERα agonist, GTx-758 (250 mg daily), in men with metastatic (mCRPC) and nonmetastatic castration-resistant prostate cancer (nmCRPC) von Yu, Evan Y., Hancock, Michael L., Babicz, Tamas, Aronson, William J., Papai, Zsuzsanna, Geczi, Lajos, Getzenberg, Robert H.

    Veröffentlicht in Journal of clinical oncology

    Volltext
    Artikel

    Zu den Favoriten
    Gespeichert in:
  6. 6
    A phase II open-label trial of GTx-758 in men with castration-resistant prostate cancer: Final analysis of the primary endpoint

    A phase II open-label trial of GTx-758 in men with castration-resistant prostate cancer: Final analysis of the primary endpoint von Yu, Evan Y., Hancock, Michael L., Babicz, Tamas, Tutrone, Ronald F., Ng, Christopher, Belkoff, Laurence H., Aronson, William J., Papai, Zsuzsanna, Geczi, Lajos, Getzenberg, Robert H.

    Veröffentlicht in Journal of clinical oncology

    Volltext
    Artikel

    Zu den Favoriten
    Gespeichert in:
  7. 7
    Double Heterozygosity for Rare Deleterious Variants in the BRCA1 and BRCA2 Genes in a Hungarian Patient with Breast Cancer

    Double Heterozygosity for Rare Deleterious Variants in the BRCA1 and BRCA2 Genes in a Hungarian Patient with Breast Cancer von Madar, László, Majoros, Viktória, Szűcs, Zsuzsanna, Nagy, Orsolya, Babicz, Tamás, Butz, Henriett, Patócs, Attila, Balogh, István, Koczok, Katalin


    Volltext
    Report

    Zu den Favoriten
    Gespeichert in:

Suchwerkzeuge: